Roivant unit settles LNP patent suit with Moderna for $2.25 billion; buyback raised to $1 billion
Genevant and Arbutus, both tied to Roivant, agreed to settle their patent infringement litigation against Moderna over LNP technology in its COVID-19 vaccines. Moderna will pay $950 million by July 8, 2026, plus a contingent $1.3 billion tied to a Federal Circuit appeal on 28 U.S.C. §1498. Roivant's board also raised its share repurchase authorization to $1.0 billion, including the previously approved $500 million.
Key points
- Moderna to pay a noncontingent $950 million lump sum on or before July 8, 2026
- Additional $1.3 billion contingent payment depends on the Federal Circuit's §1498 ruling; a partial outcome yields a prorated amount
- Board increased the share repurchase program to up to $1.0 billion, funded with cash on hand, with no expiration date
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:10 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on March 03, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.